• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    6/14/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development.

    John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus Board. Eiry's extensive background in clinical research and drug development across a diverse range of therapeutic areas adds immense value to our team of Directors and senior leaders. Eiry's experience in discovering and advancing development programs through the regulatory process, as well as her expertise in healthcare strategy, will be invaluable as we look toward the future of Amicus."

    Dr. Roberts currently serves as the Chief Medical Officer of Neurocrine Biosciences, a commercial stage biopharmaceutical company focused on the research and development of treatments for life threatening and under-addressed neurological, endocrine, and psychiatric disorders. Prior to her role at Neurocrine, Dr. Roberts spent 26 years at Eli Lilly and Company, during which she advanced through various senior and executive level roles, concluding her tenure at the company as VP of Research & Development. Roberts has extensive leadership experience in early development and translational medicine and successfully led more than 10 late-stage development programs through global regulatory approvals, as well as numerous launches. She is credited for establishing a new therapeutic area and pipeline of novel small molecule and biologics within the Lilly portfolio, and has established herself as a leader and strategic player in corporate and business development activities.

    Dr. Roberts served as Chair of the Medical Review Committee at Eli Lilly and Company, responsible for the review and approval of all integrated clinical plans in the Eli Lilly portfolio. She is an M.D. trained in pharmacology and medicine in the United Kingdom, qualifying from the University of London. Dr. Roberts continued her post-graduate clinical training in clinical pharmacology and cardiology at St. Bartholomew's Hospital and at the Royal London Hospital.

    "I am delighted to be joining the Amicus Board and contribute to the Company's mission, help grow the organization, and support the lives of those impacted by devastating rare diseases. The approach Amicus has towards drug development is driven by science and incorporates the patient perspective in every step of the process. As a member of the Board of Directors, I look forward to applying my life sciences experience to help guide the company's future growth and success," said Dr. Roberts.

    In addition, Amicus announced that Craig A. Wheeler and Burke W. Whitman were re-elected at the 2021 Annual Meeting of Stockholders.

    About Amicus Therapeutics

    Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com, and follow on Twitter and LinkedIn.

    CONTACT:

    Investors:

    Andrew Faughnan

    Sr. Director, Investor Relations

    [email protected]

    (609) 662-3809

    Media:

    Diana Moore

    Head of Global Corporate Communications

    [email protected]

    (609) 662-5079

    FOLD–G



    Primary Logo

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings